|Articles|September 17, 2020
Nitrosamine Testing: The Regulatory Aspects
Author(s)SGS
Detection of N-Nitrosodimethylamine (NDMA) impurities has led to regulatory warnings and product recalls. Pharmaceutical manufacturers must adopt a proactive approach to risk assessment and mitigation in relation to genotoxic contaminants.
Related Content
Sponsored Content
Trending on Pharmaceutical Technology
1
FDA Activity Round Up – July 2026
2
Midyear 2026 Check-In: AI, Supply Chains, and the NDC-12 Story Nobody's Watching
3
From Predictions to Reality: Mike Stenberg Assesses Pharma Manufacturing's First Half of 2026
4
EMA and EU Innovation Agency Deepen Ties to Speed Up Drug Development
5